ghk-cu 100 100mg Copper Tripeptide Australia | COA GHK-Cu 100mg Best Research Peptide

Molecular Characteristics Compound Name: hGH Fragment 176191 CAS Number: 66004-57-7 Peptide Length: 16 amino acids Molecular Formula: C78H123N23O23 Molecular Weight: ~1817 g/mol Form: Lyophilized peptide powder Purity: 99% HPLC verified Stability Profile and Storage Recommendations Store lyophilized peptide at 20C Protect from moisture and direct light exposure Avoid repeated freezethaw cycles Reconstituted solutions should be refrigerated Handle using aseptic laboratory techniques Solubility and Reconstitution Options Sterile bacteriostatic water Sterile saline solutions Buffered aqueous laboratory solutions Biochemical assay buffers Laboratory-grade solvent systems Technical Specifications product Name hGH Fragment 176191 6mg brand BioPeptides cas 66004-57-7 purity 99% (HPLC verified) unit Size 6mg vial form Lyophilized powder synthesis Solid-Phase Peptide Synthesis (SPPS) analytical HPLC and Mass Spectrometry molecular Structure Synthetic growth hormone fragment stability Stable when stored at 20C Analytical Validation and Quality Assurance High-performance liquid chromatography purity verification Mass spectrometry molecular weight confirmation Peptide structural integrity validation Batch-to-batch analytical consistency testing Peptide stability verification Regulatory and Compliance Statement hGH Fragment 176191 supplied by BioPeptides is intended strictly for laboratory and scientific research use only

When combined with personalized care plans and an active lifestyle, Tirzepatide provides an effective and sustainable weight loss solution, ultimately supporting patients in their efforts to achieve their individual health and wellness goals

BPC-157 operates primarily at the vascular and fibroblast level, driving the early angiogenic response and connective tissue rebuilding

Freezethaw cycles may: Affect molecular stability Increase aggregation risk in some formulations Reduce overall consistency of the solution Storage at 28C is typically preferred unless otherwise validated

European Medicines Agency (2025) Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products